

# LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH

## SALES WORLDWIDE

**\$8.1**  
billion

**+7.6%**<sup>1</sup>  
on organic basis\*

## STRONG PERFORMANCE ACROSS ABBOTT<sup>2</sup>

SALES ON ORGANIC BASIS\*



**+10.6%**  
MEDICAL DEVICES



**+6.6%**  
DIAGNOSTICS



**+3.8%**  
NUTRITION



**+7.9%**  
ESTABLISHED  
PHARMACEUTICALS

## NARROWED FULL-YEAR 2019 EPS GUIDANCE<sup>3</sup>

**\$3.23 TO \$3.25**

Adjusted diluted EPS midpoint reflects double-digit growth


## KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE

### FREESTYLE LIBRE

**SALES UP 68%**  
ON ORGANIC BASIS<sup>4</sup>

- ▶ FreeStyle® Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec
- ▶ Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience

**MITRACLIP**  
**SALES UP 32%**  
ON ORGANIC BASIS<sup>5</sup>




- ▶ COAPT™ Trial data show MitraClip® is cost effective, increases life expectancy and improves quality of life
- ▶ MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature

### CORE LABORATORY DIAGNOSTICS

**SALES UP 11%**  
ON ORGANIC BASIS<sup>6</sup>

- ▶ Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories
- ▶ Alinity®-S — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe



\* Organic sales growth excludes the prior year first-, second- and third-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third-quarter 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 16, 2019, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).

1. On a GAAP basis, Abbott sales increased 5.5%. 2. On a GAAP basis, Medical Devices sales increased 8.9%; Diagnostics sales increased 4.7%; Nutrition sales increased 2.0%; and Established Pharmaceuticals sales increased 4.4%. 3. Adjusted diluted EPS excludes specified items. On a GAAP basis, full-year guidance is \$2.06 to \$2.08. 4. On a GAAP basis, FreeStyle Libre sales increased 63.1%. 5. On a GAAP basis, MitraClip sales increased 30.4%. 6. On a GAAP basis, Core Laboratory Diagnostics sales increased 8.3%.

#### FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.